Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Citryll


All Data

Filters Filter refresh
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CIT-013

            Therapeutic Area: Immunology Product Name: CIT-013

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: BOM Brabant Ventures

            Deal Size: $21.0 million Upfront Cash: Undisclosed

            Deal Type: Financing July 02, 2020


            The proceeds will be used to advance the pre-clinical and clinical development of Citryll’s CIT-013 therapeutic antibody, an inhibitor of neutrophil extracellular traps (NETs) and their formation (NETosis).